摘要
目的探讨慢性肾衰患者应用促红细胞生成素对铁调素的影响。方法选取30例慢性肾衰的患者,分别检测、比较治疗前后铁代谢综合指标包括血清铁、铁蛋白、总铁结合力及血红蛋白等,同时采用酶联免疫吸附法(ELISA)测定促红细胞生成素治疗前后患者血清铁调素和白细胞介素6(IL-6)水平。结果应用促红细胞生成素后患者铁调素为(154.28±31.37)μg/L,治疗前(208.67±40.34)μg/L,治疗后明显下降(P<0.05);血红蛋白治疗前为(82.31±12.41)g/L,治疗后为(99.43±11.82)g/L,治疗后明显升高(P<0.05);同时治疗后的血清铁、转铁蛋白、总铁结合力均升高,差异有统计学意义(P<0.05),铁蛋白降低,差异有统计学意义(P<0.05);治疗后SCr无明显变化;hs-CRP治疗前为(4.53±2.11)mg/L,治疗后为(2.84±0.92)mg/L,治疗后明显降低(P<0.05);IL-6治疗前为(51.23±12.44)ng/L,治疗后为(49.95±13.56)ng/L,治疗前后无明显变化。结论促红细胞生成素能调节慢性肾衰患者体内铁调素水平而纠正贫血。
Objective To investigate the expression of serum hepcidin in chronic renal failure （CRF） patients after using erythropoietin （EPO）. Methods Totally 30 CFR patients were enrolled in this study. Serum Fe, ferritin（ FER）, total iron binding capacity （TIBC） , transferrin （TRF） and hemoglobin were measured by routine methods. The levels of serum hepcidin and interleu- kin 6 were measured by enzyme-linked immunosorbent assay（ELISA）. Data were compared between the two groups. Results Af- ter the application of EPO, the level of serum hepcidin decreased from（208.67 ± 40.34 ）μg/L to（ 154.28 ± 31.37 ）μg/L（ P 〈 O. 05 ） ;the level of hemoglobin increased from（82.31 ± 12.41 ）g/L to（99.43 ± 11.82）g/L（ P 〈 0.05 ）. After the treatment, the levels of Serum Fe, TRF and TIBC increased while the levels of FER decreased （P 〈 0.05 ）. The levels of SCr did not changed ob- viously. The levels of hs-CRP decreased from（4.53 ± 2.11 ） mg/L to（ 2.84 ± 0.92 ） mg/L（ P 〈 0.05 ） ; But the level of IL-6 did not changed significantly （ P 〉 0.05 ）. Conclusion The level of serum hepcidinl can be regulated by EPO in CRF patients and a- naemia can be improved.
出处
《中华全科医学》
2013年第9期1340-1341,共2页
Chinese Journal of General Practice
基金
安徽省高等学校科研项目(KJ2008B082)
关键词
铁调素
促红细胞生成
铁代谢
贫血
Hepeidin
Erythropoietin （ EPO ）
Iron metabolism
Anemia
